Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Accumulated Expenses: 2020-2025

Historic Other Accumulated Expenses for Foghorn Therapeutics (FHTX) over the last 4 years, with Sep 2025 value amounting to $396,000.

  • Foghorn Therapeutics' Other Accumulated Expenses rose 85.92% to $396,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $396,000, marking a year-over-year increase of 85.92%. This contributed to the annual value of $1,000 for FY2024, which is 97.22% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Other Accumulated Expenses stood at $396,000 for Q3 2025, which was up 1.02% from $392,000 recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Other Accumulated Expenses high stood at $526,000 for Q1 2025, and its period low was $1,000 during Q4 2024.
  • In the last 3 years, Foghorn Therapeutics' Other Accumulated Expenses had a median value of $226,000 in 2024 and averaged $233,300.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first spiked by 200.00% in 2022, then crashed by 97.22% in 2024.
  • Over the past 5 years, Foghorn Therapeutics' Other Accumulated Expenses (Quarterly) stood at $392,000 in 2021, then fell by 18.88% to $318,000 in 2022, then crashed by 88.68% to $36,000 in 2023, then tumbled by 97.22% to $1,000 in 2024, then spiked by 85.92% to $396,000 in 2025.
  • Its Other Accumulated Expenses was $396,000 in Q3 2025, compared to $392,000 in Q2 2025 and $526,000 in Q1 2025.